SCHEMBL29628342

SCHEMBL29628342

O=C(O)c1cccc(-c2cn[nH]c2C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD74 P04233 1/20 0.50
MIF P14174 1/20 0.50
DDT P30046 1/20 0.47
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
KMO O15229 2/20 0.46
AXL P30530 2/20 0.45
MAP2K4 P45985 2/20 0.44
MAPK1 P28482 1/20 0.44
MAPKAPK3 Q16644 1/20 0.44
MAPK6 Q16659 1/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
TDO2 P48775 1/20 0.42
PDK2 Q15119 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29628531 0.81 SYK (0.48) ROCK2ROCK1MEN1NPC1RAB9A
SCHEMBL29746173 0.76 AXL (0.42) AXLROCK2ROCK1
SCHEMBL29746203 0.72 KDM4E (0.42) MIFROCK2ROCK1NPC1RAB9A
SCHEMBL121673 0.72 AKR1C3 (0.61) AKR1C3AKR1C2KMOHDAC1HDAC6
SCHEMBL4496720 0.71 MAPK1 (0.49) CD74MIFKMOMAP2K4MAPK1
SCHEMBL16749639 0.71 KMO (0.69) CD74MIFDDTAKR1C3AKR1C2
SCHEMBL29386545 0.71 KMO (0.69) CD74MIFDDTAKR1C3AKR1C2
SCHEMBL2528069 0.70 AKR1C3 (0.55) DDTAKR1C3AKR1C2KMOHDAC1
SCHEMBL28160262 0.70 HDAC6 (0.51) DDTAKR1C3AKR1C2KMOHDAC1
SCHEMBL28334899 0.70 DDT (0.54) DDTAKR1C3AKR1C2KMOHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3997096-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2024-08-28 EP disclosed
US-20220242876-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2022-08-04 US disclosed
EP-3997096-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2022-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220242876-A1 HETEROCYCLIC COMPOUNDS CYP1B1, CYP1A1, CYP1A2 CD74 4348/4885MIF 4555/4885DDT 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.